Coprelotamab

库洛妥单抗

Report date: 2022/03/21 10:15:52

Base Information

Drug NameCoprelotamab
Drug Alias NameHerceptin biosimilar (BIOCND/Genor Biopharma)曲妥珠单抗生物仿制药 (BIOCND/Genor Biopharma)GB-221
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocndGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeL01XC03
Related LinksN/A